Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma

Figure 1

Sigma-2 ligands have a high affinity for pancreatic adenocarcinoma cell lines compared to normal cell lines. Representative FACS analysis of human (A.) and murine (B.) pancreatic adenocarcinoma cell lines treated with the FITC-conjugated Sigma-2 ligand, SW120. In Panel A, HPDE (immortalized pancreatic ductal epithelial cells) were used as a control. In Panel B, competitive inhibition of SW120 binding was demonstrated by preincubation with the Sigma-2 ligand, SW95. Pentazocine, a Sigma-1 receptor ligand, was also used as a control and did not demonstrate competitive inhibition. Experiments were performed in triplicate with comparable results.

Back to article page